Privo Technologies is a privately funded company that spun out of the world-renowned Langer Laboratory at the Massachusetts Institute of Technology (MIT) in Cambridge, Massachusetts, USA. Privo is developing a novel, nanotechnology-based drug delivery platform capable of local and systemic delivery of a constant, controlled therapeutic dose through the mucosa. This approach eliminates needles, avo
ids stomach acids, can significantly reduce toxic side effects of drugs, and allows for higher dosing where the drugs can be most effective – all of which improve patient outcomes and compliance. Privo was founded by Manijeh Goldberg who is a seasoned executive with over 20 years experience in the medical industry as an executive leader and a scientist in large and small start-up companies, one of which (Epicon) was acquired for $275M. Her 12 years of large company experience includes working for HP medical and Siemens Medical Systems. Manijeh’s MBA from MIT and MS from Harvard Medical School led to her working with Professor Robert Langer. Professor Langer has global expertise in nanotechnology and drug delivery, and is now an advisor to Privo. Privo is focused on dramatically improving human health through its novel and proprietary Mucosal Delivery Particle (MDP) platform. Privo’s platform has both small and large molecule applications. The technologies used in Privo’s platform have previously received MIT’s prestigious Deshpande Center for Technological Innovation Award as well as an award from MIT’s 100k (Best Product) for work surrounding buccal delivery of insulin.
